Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose Programmed death-1 (PD-1)/PD-1 ligand (PD-L1) axis blockades have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). We assessed the effect of platinum- based chemotherapy on tumor PD-L1 expression and its clinical implications. Materials and Methods We used immunohistochemistry to retrospectively evaluate the percentage of tumor cells with membranous PD-L1 staining (tumor proportion score) in paired tumor specimens obtained before and after platinum-based neoadjuvant chemotherapy (NACT) in 86 patients with NSCLC. We analyzed the correlation between the change in PD-L1 tumor proportion score and clinicopathologic characteristics, response to NACT, and survival. Results The PD-L1 tumor proportion score increased in a significant proportion of patients with NSCLC after platinum-based NACT (Wilcoxon signed-rank test, p=0.002). That pattern was consistent across clinically defined subgroups except for patients with partial response to NACT. Tumors from 26 patients (30.2%) were PD-L1!negative before NACT but PD-L1-positive after NACT, whereas the reverse pattern occurred in six patients (7%) (McNemar’s test, p < 0.001). Increase in PD-L1 tumor proportion score was significantly associated with lack of response to NACT (Fisher exact test, p=0.015). There was a tendency, albeit not statistically significant, for patients with an increase in PD-L1 tumor proportion score to have shorter survival. Conclusion Tumor PD-L1 expression increased after platinum-based NACT in a significant proportion of patients with NSCLC. Increase in tumor PD-L1 expression may predict poor clinical outcome.
Abstract
Purpose Programmed death-1 (PD-1)/PD-1 ligand (PD-L1) axis blockades have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). We assessed the effect of platinum- based chemotherapy on tumor PD-L1 expression and its clinical implications. Materials and Methods We used immunohistochemistry to retrospectively evaluate the percentage of tumor cells with membranous PD-L1 staining (tumor proportion score) in paired tumor specimens obtained before and after platinum-based neoadjuvant chemotherapy (NACT) in 86 patients with NSCLC. We analyzed the correlation between the change in PD-L1 tumor proportion score and clinicopathologic characteristics, response to NACT, and survival. Results The PD-L1 tumor proportion score increased in a significant proportion of patients with NSCLC after platinum-based NACT (Wilcoxon signed-rank test, p=0.002). That pattern was consistent across clinically defined subgroups except for patients with partial response to NACT. Tumors from 26 patients (30.2%) were PD-L1!negative before NACT but PD-L1-positive after NACT, whereas the reverse pattern occurred in six patients (7%) (McNemar’s test, p < 0.001). Increase in PD-L1 tumor proportion score was significantly associated with lack of response to NACT (Fisher exact test, p=0.015). There was a tendency, albeit not statistically significant, for patients with an increase in PD-L1 tumor proportion score to have shorter survival. Conclusion Tumor PD-L1 expression increased after platinum-based NACT in a significant proportion of patients with NSCLC. Increase in tumor PD-L1 expression may predict poor clinical outcome.
참고문헌 (29)
- Reck M, "Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer", N Engl J Med, 375, pp.1823~1833 (2016)
- Gandhi L, "Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer", N Engl J Med, 378, pp.2078~2092 (2018)
- Herbst RS, "Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer(KEYNOTE-010) : a randomised controlled trial", Lancet, 387, pp.1540~1550 (2016)
- Brahmer J, "Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer", N Engl J Med, 373, pp.123~135 (2015)
- Borghaei H, "Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer", N Engl J Med, 373, pp.1627~1639 (2015)
- Rittmeyer A, "Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer(OAK) : a phase 3, open-label, multicentre randomised controlled trial", Lancet, 389, pp.255~265 (2017)
- Sul J, "FDA approval summary : pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1", Oncologist, 21, pp.643~650 (2016)
- Parra ER, "Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches", J Immunother Cancer, 6, pp.48~ (2018)
- Sheng J, "Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer", Sci Rep, 6, pp.20090~ (2016)
- Fujimoto D, "Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients", Sci Rep, 7, pp.11373~ (2017)
- Song Z, "Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma", Lung Cancer, 99, pp.166~171 (2016)
- Rojko L, "Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients", J Cancer Res Clin Oncol, 144, pp.1219~1226 (2018)
- Zhang P, "Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy", Cancer Sci, 107, pp.1563~1571 (2016)
- Ettinger DS, "Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology", J Natl Compr Canc Netw, 15, pp.504~535 (2017)
- Kelland L, "The resurgence of platinum-based cancer chemotherapy", Nat Rev Cancer, 7, pp.573~584 (2007)
- Hato SV, "Molecular pathways : the immunogenic effects of platinum-based chemotherapeutics", Clin Cancer Res, 20, pp.2831~2837 (2014)
- Lesterhuis WJ, "Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice", J Clin Invest, 121, pp.3100~3108 (2011)
- Rizvi NA, "Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer", J Clin Oncol, 34, pp.2969~2979 (2016)
- Liu SV, "Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer", Eur J Cancer, 101, pp.114~122 (2018)
- Goldstraw P, "The IASLC Lung Cancer Staging Project : proposals for the revision of the TNM stage groupings in the forthcoming(seventh)edition of the TNM Classification of malignant tumours", J Thorac Oncol, 2, pp.706~714 (2007)
- Herbst RS, "Predictive correlates of response to the anti-PD-L1antibody MPDL3280A in cancer patients", Nature, 515, pp.563~567 (2014)
- Fehrenbacher L, "Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial", Lancet, 387, pp.1837~1846 (2016)
- Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
- Tsao MS, "PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer", Ann Oncol, 28, pp.882~889 (2017)
- Sun JM, "Prognostic significance of PD-L1 in patients with non-small cell lung cancer : a large cohort study of surgically resected cases", J Thorac Oncol, 11, pp.1003~1011 (2016)
- Wang A, "The prognostic value of PD-L1 expression for non-small cell lung cancer patients : a meta-analysis", Eur J Surg Oncol, 41, pp.450~456 (2015)
- Tokito T, "Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy", Eur J Cancer, 55, pp.7~14 (2016)
- Cooper WA, "PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma", Lung Cancer, 89, pp.181~188 (2015)
- O'Brien ME, "EORTC-ETOP randomized, phase 3 trial with anti-PD-1monoclonal antibody pembrolizumab versus placebo for patients with early stage non-small cell lung cancer (NSCLC)after resection and standard adjuvant chemotherapy: PEARLS (NCT02504372)", J Clin Oncol, 34(15 Suppl), pp.TPS8571~ (2016)